Merck and UAB Recruiting 16 to 26 Year Old Mothers Who Just Gave Birth to Enroll in Gardasil 9 Vaccine Trials

The University of Alabama at Birmingham (UAB) in collaboration with Merck pharmaceutical company is planning to conduct Gardasil 9 vaccine trials on postpartum mothers between the ages of 16 to 26 immediately after giving birth at the UAB hospital. According to, the desired outcome of this study is to have more young women vaccinated with the Gardasil vaccine, because they do not believe enough young women are being vaccinated: "Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine." Previous studies on the Gardasil vaccine have shown that young women who are in the hospital due to giving birth are open to receiving the Gardasil vaccine, particularly Hispanic populations: "The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations." Merck and UAB want to test the vaccine on 16 to 26 year old postpartum mothers because "the immune response in young women is less robust than in adolescents," and because "no studies have examined immunogenicity in postpartum women specifically." Therefore, 16 to 26 year old young mothers who have just given birth at the UAB hospital will become test subjects of the Gardasil 9 vaccine. Will these young mothers in Alabama have sufficient information to make the decision to participate in these Gardasil vaccine trials just after giving birth? Will they understand the potential risks for harm, which includes heart disease (POTS), premature menopause (“Primary Ovarian Failure”) and a whole list of autoimmune disorders that have been hidden from the public but revealed by a 2017 study done in Mexico?

Facts About the Gardasil Vaccine: Teens Don’t Get Cervical Cancer

Despite no recorded outbreak of cervical cancer nor change in sexual behavioral risks among teenagers, Gardasil vaccine was studied for less than two years prior to its approval. This was particularly curious since the cancer the vaccine purports to prevent does not present itself for 20-30 years. And, while the drug was tested only on women aged 16-23 before it became the first licensed HPV vaccine in the United States, today it is recommended for boys and girls as young as 10 years old. Moreover, Gardasil was not tested on people with health problems nor in combination with all the other vaccines routinely administered to American adolescents, such as Tdap and meningococcal vaccines. Contrary to the ad campaign created by Merck that depicts tragic-looking teenagers asking their parents why they weren’t protected from getting cancer, there have been no reports of any teen contracting cervical cancer from HPV ever.

International Study: An Honest Look at the Statistics Shows that the HPV Vaccine is Not Safe

A new study was published earlier this month (July 2017) in the journal Clinical Rheumatology looking at serious adverse events after HPV vaccination. The title of the study is: Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. This is an international peer-reviewed journal that has been around since 1945. It is the "Journal of the International League of Associations for Rheumatology," and is the official journal of the Belgian Rheumatology Society. The study was conducted by doctors from the Rheumatology Department and the Immunology Department at the National Institute of Cardiology in Mexico City. The results of their study found: 1. The lack of inert placebo in the vast majority of prelicensure HPV vaccine randomized studies, 2. Large randomized trials disclosed significantly more severe adverse events in the tested HPV vaccine cohort, 3. Pooled safety analysis found more post-immunization symptoms in bivalent HPV vaccine vs. hepatitis A vaccine, 4. Post-marketing HPV vaccine adverse events case series describe similar cluster of symptoms than those reported in pre-clinical trials, 5. The European Medicines Agency report on HPV vaccine safety looked at specific diagnoses and not at symptoms clusters, 6. In-depth analysis of some supportive post-marketing HPV vaccine safety studies discloses disquieting findings. The study found the statistics regarding the new Gardasil 9 particularly troubling, as the statistics suggest that severe harm is suffered every 140 injections, and the number needed to vaccinate in order to see any perceived benefits to the vaccine is 1757. Such a critical study of any vaccine would probably never get published in the United States, as it is considered professional suicide to criticize the extremist position that all vaccines are safe and effective, and that the "science is settled" regarding vaccines.

Stronger More Toxic Gardasil Vaccine Approved by FDA: Will More Girls Suffer and Die?

The FDA has just approved the use of a reportedly "new and improved" version of Gardasil, which will be marketed as Gardasil 9. According to the FDA approval letter, this action was taken without consultation with VRBPAC (the Vaccines and Related Biological Products Advisory Committee) which is responsible for reviewing and evaluating data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products. A reading of the package insert for the new Gardasil vaccine reveals that Gardasil 9 has more than DOUBLE the amount of toxic aluminum, increased auto immune disorders and fetal deaths among pregnant women during drug trials, and recorded a rate of 2,300 serious adverse events to try and prevent 7.9 cases of cervical cancer. Will you or your children be getting the "new and improved" HPV Gardasil vaccine?